Cargando…
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430309/ http://dx.doi.org/10.1097/01.HS9.0000847060.14020.7d |
| _version_ | 1784779726705917952 |
|---|---|
| author | Mascarenhas, J. Harrison, C. N. Kiladjian, J.-J. Komrokji, R. S. Koschmieder, S. Vannucchi, A. M. Berry, T. Redding, D. Sherman, L. Dougherty, S. Peng, L. Sun, L. Huang, F. Wan, Y. Feller, F. M. Rizo, A. Verstovsek, S. |
| author_facet | Mascarenhas, J. Harrison, C. N. Kiladjian, J.-J. Komrokji, R. S. Koschmieder, S. Vannucchi, A. M. Berry, T. Redding, D. Sherman, L. Dougherty, S. Peng, L. Sun, L. Huang, F. Wan, Y. Feller, F. M. Rizo, A. Verstovsek, S. |
| author_sort | Mascarenhas, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430309 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94303092022-08-31 P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR Mascarenhas, J. Harrison, C. N. Kiladjian, J.-J. Komrokji, R. S. Koschmieder, S. Vannucchi, A. M. Berry, T. Redding, D. Sherman, L. Dougherty, S. Peng, L. Sun, L. Huang, F. Wan, Y. Feller, F. M. Rizo, A. Verstovsek, S. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430309/ http://dx.doi.org/10.1097/01.HS9.0000847060.14020.7d Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Mascarenhas, J. Harrison, C. N. Kiladjian, J.-J. Komrokji, R. S. Koschmieder, S. Vannucchi, A. M. Berry, T. Redding, D. Sherman, L. Dougherty, S. Peng, L. Sun, L. Huang, F. Wan, Y. Feller, F. M. Rizo, A. Verstovsek, S. P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR |
| title | P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR |
| title_full | P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR |
| title_fullStr | P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR |
| title_full_unstemmed | P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR |
| title_short | P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR |
| title_sort | p1048: myf3001: a randomized open label, phase 3 study to evaluate imetelstat versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis refractory to janus kinase inhibitor |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430309/ http://dx.doi.org/10.1097/01.HS9.0000847060.14020.7d |
| work_keys_str_mv | AT mascarenhasj p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT harrisoncn p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT kiladjianjj p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT komrokjirs p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT koschmieders p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT vannucchiam p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT berryt p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT reddingd p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT shermanl p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT doughertys p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT pengl p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT sunl p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT huangf p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT wany p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT fellerfm p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT rizoa p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor AT verstovseks p1048myf3001arandomizedopenlabelphase3studytoevaluateimetelstatversusbestavailabletherapyinpatientswithintermediate2orhighriskmyelofibrosisrefractorytojanuskinaseinhibitor |